ANAB
AnaptysBio Inc

2,043
Mkt Cap
$1.79B
Volume
1.46M
52W High
$68.39
52W Low
$15.40
PE Ratio
-119.82
ANAB Fundamentals
Price
$62.37
Prev Close
$64.72
Open
$64.47
50D MA
$53.61
Beta
0.79
Avg. Volume
451,480.49
EPS (Annual)
-$0.4601
P/B
46.96
Rev/Employee
$2.26M
$1,373.19
Loading...
Loading...
News
all
press releases
AnaptysBio (NASDAQ:ANAB) Sees Strong Trading Volume - Time to Buy?
AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume - Here's Why...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
UBS Group Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price
UBS Group upped their price target on AnaptysBio from $70.00 to $90.00 and gave the stock a "buy" rating in a research note on Tuesday...
MarketBeat·5d ago
News Placeholder
AnaptysBio, Inc. $ANAB Shares Purchased by Granahan Investment Management LLC
Granahan Investment Management LLC raised its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 12.2% in the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·5d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month High - Should You Buy?
AnaptysBio (NASDAQ:ANAB) Sets New 1-Year High - Time to Buy...
MarketBeat·5d ago
News Placeholder
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·6d ago
News Placeholder
First Light Asset Management LLC Sells 2,549,432 Shares of AnaptysBio, Inc. $ANAB
First Light Asset Management LLC lessened its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 72.0% during the third quarter, according to its most recent filing with the...
MarketBeat·6d ago
News Placeholder
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock
Wedbush increased their target price on AnaptysBio from $60.00 to $75.00 and gave the stock an "outperform" rating in a research note on Thursday...
MarketBeat·10d ago
News Placeholder
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga outlined progress on the company's planned separation into two entities, provided an update on its royalty streams and ongoing litigation related to GSK's...
MarketBeat·10d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week High - What's Next?
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High - Still a Buy...
MarketBeat·11d ago
News Placeholder
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible
AnaptysBio (NASDAQ:ANAB) is preparing to separate its business into two entities, with CEO Daniel Faga telling Barclays Senior Biotech Analyst Gena Wang that the company expects to create a new...
MarketBeat·11d ago
<
1
2
...
>

Latest ANAB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.